Clenbutos (Clenbuterol)

About the Product

Clenbutos is a research compound from Driada Medical, presented as a solution containing Clenbuterol. Clenbuterol is a synthetic sympathomimetic amine and selective agonist of the β2-adrenergic receptor (β2-AR). Its chemical formula is C₁₂H₁₈Cl₂N₂O·HCl, with a molecular weight of 313.7 g/mol. Originally developed and widely used as a bronchodilator for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD), it has also been extensively studied for its metabolic and repartitioning effects, including increased lean muscle mass and reduced fat deposition.

The product is intended for laboratory research use only and features an integrated QR code on the packaging for detailed product verification.

• Product Name: Clenbutos (Clenbuterol)

• Brand: Driada Medical

• Form: Solution for research applications

• For Research Use Only.

Research Applications & Mechanism of Action

• Selective β2-Adrenergic Receptor Agonist: Clenbuterol functions as a potent agonist at the β2-adrenergic receptor (β2-AR). Activation of this receptor stimulates adenyl cyclase, increasing intracellular cyclic AMP (cAMP) levels, which in turn activates protein kinase A (PKA) and initiates a cascade of metabolic effects including lipolysis and protein synthesis.

• Metabolic Repartitioning: Clenbuterol is well-known for its ability to increase lean body mass and decrease fat mass in research models. This repartitioning effect has been studied across multiple species, with observed muscle hypertrophy (increased muscle fiber size) and reduced adiposity. Studies have demonstrated that clenbuterol can increase the weight of skeletal muscles and carcass protein content while reducing carcass fat content.

• Lipolytic Effects: Clenbuterol stimulates lipolysis (fat breakdown) in adipocytes. In research studies, clenbuterol has been shown to increase free glycerol release (a marker of lipolysis) in cultured adipocytes by up to 190% of control values. It also reduces hepatic lipid accumulation and improves fatty liver conditions in diet-induced obesity models.

• Glucose Metabolism & Insulin Sensitivity Research: Recent research has demonstrated that prolonged treatment with low-dose clenbuterol improves glucose tolerance and whole-body insulin sensitivity in diet-induced obese (DIO) mice. These effects are mediated through:

  • Stimulation of basal glucose uptake in skeletal muscle, independent of insulin.

  • Improved hepatic insulin sensitivity and reduced liver glycogen levels.

  • Reduction of hepatic steatosis (fatty liver).

• Muscle Physiology & Protein Anabolism: Clenbuterol promotes protein synthesis and reduces protein degradation in skeletal muscle, making it a valuable tool for studying:

  • Muscle hypertrophy and fiber type composition (especially type II fiber hypertrophy).

  • Muscle wasting conditions such as cachexia, sarcopenia, and disuse atrophy.

  • Mechanisms of muscle protein turnover.

• Neuroprotective Research: Clenbuterol has demonstrated neuroprotective properties in research models. It has been shown to induce growth factor mRNA, activate astrocytes, and protect rat brain tissue against ischemic damage. Studies have also reported improvements in motor coordination, respiratory function, and survival in neurological disease models.

• Anti-Inflammatory Effects: Research indicates that clenbuterol can inhibit the release of pro-inflammatory cytokines such as TNF-α and IL-1β. This anti-inflammatory activity provides a research avenue for studying inflammatory conditions alongside its metabolic effects.

Research & Scientific Background

• Chemical Background: Clenbuterol (4-amino-3,5-dichloro-α-[[(1,1-dimethylethyl)amino]methyl]benzenemethanol hydrochloride) is a synthetic compound structurally related to catecholamines but with a longer duration of action. It exhibits a β2/β1 receptor selectivity ratio of approximately 4.0.

• Clinical Context: Clenbuterol has been clinically used as a bronchodilator for the management of chronic airways obstruction and asthma. However, its use in this context has been largely superseded by other medications. It has also been investigated for therapeutic applications in muscle-wasting conditions, cardiac cachexia, and neurological disorders.

• Lipolysis & Fat Reduction Research: Clenbuterol stimulates lipolysis through β-adrenergic receptor activation and cAMP-mediated pathways. Studies in animal production have consistently demonstrated that β-agonists like clenbuterol reduce carcass fat and increase protein deposition across various species. The effect is observed with both oral and parenteral administration.

• Glucose & Insulin Research: The effects of clenbuterol on glucose metabolism are acute vs. chronic:

  • Acute administration: Increases blood glucose and insulin levels due to enhanced hepatic glucose output.

  • Chronic administration: Improves fasting blood glucose, glucose tolerance, and insulin sensitivity, likely due to enhanced peripheral glucose clearance in skeletal muscle and reduced hepatic glucose output.

• Muscle Hypertrophy Research: Clenbuterol promotes hypertrophy of both type I and type II muscle fibers, but the increase in type II fibers is typically greater. This is associated with increased nitrogen retention and protein synthesis.

• Age, Sex & Genetic Variability Studies: Research has explored how factors such as age, sex, and genetic background influence responses to clenbuterol. Observations include:

  • Age effects: Possible lower efficacy in young animals, potentially related to endocrine status.

  • Sex effects: Some studies report sex-specific responses, with effects observed in females but not males in certain models.

  • Genetic polymorphisms: Variations in the β2-adrenergic receptor gene (ADRB2), adrenergic signaling components, and metabolic enzymes may influence individual responses. Additional research is needed to fully characterize these genetic factors, which could lead to personalized approaches in metabolic studies.

• Dose-Dependent Effects: Research has demonstrated that beneficial metabolic effects can be achieved with very low doses (e.g., in the microgram range), which may reduce potential side effects.